Enterprise Value
14.18B
Cash
12.5B
Avg Qtr Burn
N/A
Short % of Float
0.00%
Insider Ownership
65.11%
Institutional Own.
18.18%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
COMIRNATY (BNT162b2) Details COVID-19, Infectious disease | Approved Quarterly sales | |
BNT316 (ONC-392) Details Non-small cell lung carcinoma, Cancer, Lung cancer | Phase 3 Initiation | |
BNT113 Details Head and neck cancer, Human papillomavirus | Phase 2 Data readout | |
Phase 2 Data readout | ||
Autogene cevumeran (BNT122) (RO7198457) Details Solid tumor/s, Colorectal cancer | Phase 2 Data readout | |
Phase 2 Interim update | ||
Autogene cevumeran (BNT122) (w/ with atezolizumab and chemotherapy) Details Solid tumor/s, Pancreatic cancer, Cancer | Phase 2 Initiation | |
BNT-211 Details Solid tumor/s, Cancer | Phase 1/2 Data readout | |
BNT323 (DB-1303) Details Cancer, Solid tumor/s | Phase 1/2 Data readout | |
BNT-167 Details Vaccine, Shingles | Phase 1/2 Update | |
Autogene Cevumeran (BNT122) (w/ atezolizumab) Details Solid tumor/s, Non-small cell lung carcinoma, Bladder cancer, Melanoma | Phase 1/2 Update | |
BNT-164 Details Vaccine, Tuberculosis | Phase 1 Update |